Design a novel 5HT2c agonist for the treatment of serotonin related disorders

被引：0
|
作者：
Liu, Kevin K-C. [1 ]
机构：
[1] Pfizer Inc, Discovery Chem, La Jolla, CA 92121 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2009年 / 238卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
80-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [31] AGONIST AFFINITIES FOR THE SEROTONIN 5-HT1C RECEPTOR
    HARTIG, P
    YAGALOFF, K
    HANSEN, A
    FEDERATION PROCEEDINGS, 1986, 45 (03) : 435 - 435
  • [32] Agonist properties of N,N-Dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors
    Smith, RL
    Canton, H
    Barrett, RJ
    Sanders-Bush, E
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1998, 61 (03) : 323 - 330
  • [33] Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity
    Nigro, Stefanie C.
    Luon, Darren
    Baker, William L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (07) : 839 - 848
  • [34] A 5-HT2C receptor agonist for the treatment of obesity?
    Van Baak, M
    Lentjes, M
    Mujakovic, S
    Slaap, B
    Saris, W
    OBESITY RESEARCH, 2003, 11 : A110 - A111
  • [35] Mutant 5HT2C serotonin receptors display ligand binding properties consistent with constitutive activity.
    HerrickDavis, K
    Roe, L
    Casey, C
    Teitler, M
    FASEB JOURNAL, 1996, 10 (03): : 774 - 774
  • [36] A NOVELSEROTONIN 5HT2C AGONIST/5HT2A-2B ANTAGONIST SELECTIVELY DECREASES ETHANOL SELF ADMINISTRATION AND INHIBITS THE ALCOHOL DEPRIVATION EFFECT
    Kasper, J.
    MacFadyen, K.
    Tikamdas, R.
    Kim, M. S.
    Canal, C. E.
    Booth, R.
    Peris, J.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2012, 36 : 100A - 100A
  • [37] A Novel Synthesis of Pimavanserin: A Selective Serotonin 5-HT2A Receptor Inverse Agonist
    Hu, Kun
    Zhang, Meiju
    Wu, Dongdong
    Xie, Yuxuan
    Ren, Jie
    ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL, 2020, 52 (01) : 69 - 76
  • [38] A Novel Aminotetralin-Type Serotonin (5-HT)2C Receptor-Specific Agonist and 5-HT2A Competitive Antagonist/5-HT2B Inverse Agonist with Preclinical Efficacy for Psychoses
    Canal, Clinton E.
    Morgan, Drake
    Felsing, Daniel
    Kondabolu, Krishnakanth
    Rowland, Neil E.
    Robertson, Kimberly L.
    Sakhuja, Rajeev
    Booth, Raymond G.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 349 (02): : 310 - 318
  • [39] 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia
    Ellingrod, VL
    Perry, PJ
    Lund, BC
    Bever-Stille, K
    Pleming, F
    Holman, TL
    Miller, D
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (06) : 622 - 624
  • [40] Discovery of SCA-136, a novel 5-HT2C agonist, for the treatment of Schizophrenia
    Ramamoorthy, P. Siva
    Beyer, Chad
    Brennan, Julie
    Dunlop, John
    Gove, Stacey
    Grauer, Steve
    Harrison, Boyd L.
    Lin, Qian
    Malberg, Jessica
    Marquis, Karen
    Mazandarani, Hossein
    Piesla, Mike
    Pulicicchio, Claudine
    Rosenzwieg-Lipson, Sharon
    Sabb, Ann-Marie
    Schechter, Lee
    Stack, Gary
    Zhang, Jean
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
12345